Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 8/20 | 0.53 |
| ▸ | MAOA | P21397 | 6/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7251253 | 0.82 | DYRK1A (0.49) | MAOADYRK1AMAPTSMN1; SMN2 | |
| SCHEMBL7250798 | 0.81 | KIF11 (0.49) | KIF11MAOADYRK1ANPC1MAPT | |
| SCHEMBL7517830 | 0.79 | KIF11 (0.54) | KIF11MAOANPC1MAPTRAB9A | |
| SCHEMBL31756633 | 0.79 | KIF11 (0.62) | KIF11MAOADYRK1AMAPTSMN1; SMN2 | |
| SCHEMBL7251769 | 0.78 | MAOA (0.41) | KIF11MAOADYRK1ANPC1MAPT | |
| SCHEMBL7255175 | 0.78 | CTSV (0.60) | KIF11MAOASMN1; SMN2 | |
| SCHEMBL29539315 | 0.78 | KIF11 (0.81) | KIF11MAPT | |
| SCHEMBL2606005 | 0.78 | KIF11 (0.81) | KIF11MAPT | |
| SCHEMBL7256163 | 0.76 | KMT2A (0.61) | KIF11MAOA | |
| SCHEMBL1586530 | 0.76 | KDM4E (0.54) | NPC1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030040538-A1 | Novel substituted tricyclic compounds | ASAHI-KASEI KABUSHIKI KAISHA (JP) | 2003-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040538-A1 | Novel substituted tricyclic compounds | CPT1A, CBR1, NR1H3 | KIF11 4358/4885MAOA 2743/4885DYRK1A 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.